Platinum-Sensitive Ovarian Cancer – Unmet Medical Need Beyond PARP Inhibitors, Industry Supported Symposium

Activity Overview

The GOG Foundation, Inc., GOG Partners and Mersana Therapeutics welcomes gynecologic oncologists, oncologists, advanced practitioners (NP/PA/PharmD), and other clinicians who treat patients with gynecologic malignancies to view the Platinum Sensitive Ovarian Cancer: Unmet Medical Need Beyond PARP Inhibitors symposium enduring educational materials that were presented at the 2022 IGCS Annual Global Meeting.

This symposium was developed by The GOG Foundation, Inc. in partnership with Mersana Therapeutics.

Target Audience

The target audience for this activity is community and academic gynecologic oncologists, oncologists, advanced practitioners (NP/PA/PharmD), and other providers who treat patients with gynecologic malignancies.

Learning Objectives

Upon completion of the activities in this series, learners will demonstrate:

  • Identify opportunities beyond PARP inhibitors for patients with PSOC
  • Understand emerging data and what could be next beyond PARP inhibitors
  • Discuss unmet medical need in PSOC post standard of care

Moderator


Dr. Kathleen Moore

Faculty


Dr. Ramez Eskander

Dr. Katherine Fuh

Dr. Antonio González Martín

Agenda & Presentation Materials

Platinum Sensitive Ovarian Cancer: Unmet Medical Need Beyond PARP Inhibitors, Industry Supported Symposium at the 2022 IGCS Annual Global Meeting

Presented at the 2022 IGGCS Annual Global Meeting on Saturday, October 1, 2022

Enduring Educational Materials will be available on demand for six months following the live presentation. 

To access the recording of this symposium, please click the button below.  Once you have completed the registration, a confirmation email will be sent to the email address you provide and will include a link to access the recording.  To view the presentation slides, you may click the View Presentation links in the agenda below.

Register To Access the Symposium Recording

12:35 pm – 12:45 pm
Welcome & Introduction
Kathleen Moore, MD, Stephenson Cancer Center, University of Oklahoma
12:45 pm – 1:05 pm
PARP Inhibitors in Frontline Maintenance: The Evolving Treatment Paradigm – View Presentation
Ramez Eskander, MD, University of California San Diego
1:05 pm – 1:15 pm
Audience Response: Frontline Treatment Decisions for HRP Disease
Kathleen Moore, MD, Stephenson Cancer Center, University of Oklahoma
1:15 pm – 1:35 pm
Post PARP Inhibition Data in Platinum-Sensitive Recurrent Disease– View Presentation
Katherine Fuh, MD, PhD, University of California San Francisco
1:35 pm – 1:40 pm
Audience Response: What’s next after PARP inhibition
Kathleen Moore, MD, Stephenson Cancer Center, University of Oklahoma
1:40 pm – 2:00 pm
Antibody-Drug Conjugates (ADCs) and Ongoing Trials: UPLIFT, SORAYA, UP-NEXT and GLORIOSA  – View Presentation
Antonio González Martín, MD, PhD, Clínica Universidad de Navarra
2:00 pm – 2:05 pm
Q&A and Closing Remarks – View Presentation
All Faculty